Moreover, toxicity of the antidiabetic PPARγ agonist troglitazone, which has been withdrawn from the market due to its association with idiosyncratic DILI and liver failures in around 1 in 10 000-treated patients (Kohlroser et al., 2000), was clearly detected, whereas its nonhepatotoxic structural analogue rosiglitazone did not indicate any hepatic liabilities (Figure 5B). The gene discussed is PPARG; the disease is liver failure.